science wire

« BACK

Pharmacology



Results 1101 - 1150 of 1505.


Health - Pharmacology - 23.05.2014
Alcon receives positive CHMP opinion for Simbrinza , a new fixed-dose combination medicine to treat patients with glaucoma
Simbrinza reduced intraocular pressure in two Phase III studies by 23%-34%, 25%-37% respectively, providing strong efficacy, sustained control throughout the day Only beta blocker-free, fixed-dose co

Health - Pharmacology - 23.05.2014
Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure
CHMP confirms negative opinion following re-examination of RLX030 - further evidence is required Novartis aims to resubmit for approval with data from ongoing second Phase 3 study (RELAX-AHF-2) Basel, May 23, 2014 - Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion for the use of RLX030 (serelaxin) in the treatment of acute heart failure (AHF) indicating that further evidence is required for a license to be granted in the EU.

Pharmacology - Health - 22.05.2014
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
Pivotal data in ALK+ NSCLC for Zykadia(TM); recently approved by US FDA, marking fastest oncology approval under Breakthrough Therapy designation First presentation of pivotal data from Phase III tri

Health - Pharmacology - 21.05.2014
Novartis announces positive results at ATS for once-daily Ultibro Breezhaler versus combination therapy (tiotropium plus formoterol)
QUANTIFY study met primary endpoint demonstrating non-inferiority of Ultibro Breezhaler vs tiotropium 18 mcg plus formoterol 12 mcg in improving health-related quality of life outcomes , QUANTIFY stu

Pharmacology - Health - 19.05.2014
Novartis announces exclusive agreement to extend leadership in ophthalmology, leveraging novel anti-PGDF therapy Fovista
Novartis acquires exclusive ex-US rights to Fovista from Ophthotech; upfront payment of USD 200 million plus potential future recruitment and other milestone payments; additionally Ophthotech to rece

Pharmacology - Health - 16.05.2014
FDA issues Complete Response Letter for RLX030 for acute heart failure
Agency states further evidence of the efficacy of RLX030 is required for US approval Second phase III study RELAX-AHF-2 progressing well - Novartis intends to resubmit NDA with additional data when available Basel, May 16, 2014 - Novartis announced today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RLX030 (serelaxin) for the treatment of acute heart failure (AHF), stating that further evidence on the efficacy of RLX030 is required for a US license to be granted.

Pharmacology - Innovation - 15.05.2014
Novartis settles patent litigation on Gleevec (imatinib mesylate) with Sun Pharma subsidiary
Litigation settlement upholds validity of US patents covering polymorphic forms of Gleevec and permits Sun Pharma subsidiary to launch a generic version on February 1, 2016 Patents are vital to the a

Pharmacology - Health - 09.05.2014
Novartis data at ARVO 2014 confirm transformational real world outcomes and highlight the safety profile of Lucentis
LUMINOUS, the largest ongoing trial in medical retina, presented 1-year results on the effectiveness and safety profile of Lucentis in patients with wet AMD COMRADE-B study indicates BRVO patients treated with Lucentis had significantly higher vision gains at month 6 compared with dexamethasone New real-world data demonstrates significant differences in rates of endophthalmitis with aflibercept and Lucentis Basel, May 9, 2014 - Novartis reports

Health - Pharmacology - 05.05.2014
Novartis drug Signifor LAR shows superior efficacy in acromegaly patients
Acromegaly, an endocrine disorder resulting from elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, is associated with high mortality[1,2] Phase III data show patients on p

Health - Pharmacology - 30.04.2014
Novartis once-daily Ultibro Breezhaler showed superior efficacy versus Seretide * for COPD patients
Ultibro Breezhaler demonstrated superiority in lung function compared to Seretide Accuhaler * in chronic obstructive pulmonary disease ( COPD) patients with or without exacerbations in the previous year Primary and key secondary objectives met in pivotal Phase III LANTERN study Positive results to be part of the regulatory submission for Ultibro Breezhaler in China later this year Basel, April 30, 2014 - Novartis today announced positive first r

Pharmacology - Health - 30.04.2014
Novartis announces presentation of data at AAN showing Gilenya slowed the rate of brain volume loss in MS patients
MS patients have accelerated brain volume loss (up to 3-5 times faster than people without MS), which is associated with physical & cognitive loss of function Data at AAN showed significantly more Gilenya-treated patients (vs.

Health - Pharmacology - 29.04.2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Zykadia (ceritinib) demonstrated an overall response rate of 54.6% in patients with ALK+ metastatic NSCLC who have no other treatment option Median duration of response to Zykadia was 7&period

Health - Pharmacology - 29.04.2014
CHMP recommends EU label expansion of Novartis’ Gilenya and data at AAN confirm efficacy on pre-treated MS patients
CHMP has recognized Gilenya's favorable benefit/risk profile and recommends EU label expansion to patients not responding to DMTs beyond interferon AAN data: Gilenya reduces relapse rates, new MRI lesion counts, brain volume loss & disability progression in pre-treated MS patients with high disease activity Gilenya is the only oral DMT that is effective across four key measures of MS (relapse rates, MRI lesions, brain volume loss and disabil

Health - Pharmacology - 25.04.2014
FDA Approves Roche’s HPV Test for First-Line Primary Screening for Cervical Cancer
FDA Approves Roche's HPV Test for First-Line Primary Screening for Cervical Cancer Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older Roche announced today that the U.S. Food and Drug Administration (FDA) approved the cobas HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older.

Health - Pharmacology - 25.04.2014
Novartis’ INSTEAD study for Onbrez Breezhaler in patients with moderate COPD meets primary objective
Results confirm non-inferiority of Onbrez Breezhaler (indacaterol) in lung function compared to Seretide * (salmeterol/fluticasone) in the studied population In INSTEAD study, patients with moderate COPD and no exacerbations in the past year were switched from salmeterol/fluticasone to Onbrez Breezhaler Study showed similar symptomatic benefits in terms of shortness of breath and health status in patients treated with Onbrez Breezhaler compared

Business / Economics - Pharmacology - 24.04.2014
Novartis delivered solid sales and profit growth in the first quarter of 2014
Net sales of USD 14.0 billion up 1% (+3% cc ) with all divisions contributing to growth (cc); core operating leverage (cc) driven by Pharmaceuticals and lower Corporate costs Operating income

Pharmacology - Health - 23.04.2014
New data at AAN to confirm efficacy of Novartis’ Gilenya across four key measures of MS disease activity, including brain volume loss
Gilenya reduced relapse rates, new MRI lesion counts, brain volume loss and disability progression in previously-treated MS patients with high disease activity Data at AAN showed significantly more Gilenya-treated patients (vs.

Business / Economics - Pharmacology - 22.04.2014
Novartis announces portfolio transformation
Acquires GSK oncology products, strengthening Novartis' leading Oncology business with novel therapies and becomes GSK's preferred commercialization partner for its oncology pipeline Combines Novarti

Pharmacology - Business / Economics - 09.04.2014
Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz
Basel, April 9, 2014 - Novartis announced today the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014.

Health - Pharmacology - 07.04.2014
Novartis meningitis B vaccine Bexsero receives FDA Breakthrough Therapy designation in the US
The designation highlights the potential of Bexsero to meet the urgent need for a licensed vaccine in the US against unpredictable and devastating meningitis B Bexsero, already approved in Europe, Ca

Health - Pharmacology - 07.04.2014
Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
One million antimalarial treatments donated by Novartis, matching one million treatments funded through Malaria No More's Power of One campaign Power of One enables the public to fund malaria tests a

Pharmacology - Health - 03.04.2014
Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways
More than 50 abstracts highlight breadth and depth of Novartis Oncology pipeline and ability to test various combinations early to target multiple pathways Data show activity of investigational compo

Pharmacology - Health - 31.03.2014
PARADIGM-HF trial of Novartis’ LCZ696 for chronic heart failure closes early based on strength of interim results
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 27.03.2014
Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 26.03.2014
Study published in NEJM showed LDK378 demonstrated an overall response rate of 58% in patients with ALK+ NSCLC
Novartis study published in NEJM showed LDK378 demonstrated an overall response rate of 58% in patients with ALK+ NSCLC Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months Patients with this type of lung cancer, especially those for whom prior therapies have failed, are in need of new treatment options[1] Data served as the basis for regulatory application to the US Food and D

Pharmacology - Health - 22.03.2014
New phase III psoriasis data show rapid, significant skin clearance
New phase III psoriasis data show rapid, significant skin clearance and convenient administration with Novartis' secukinumab (AIN457) Pivotal phase III FEATURE and JUNCTURE studies met primary and pre-specified secondary endpoints, showing high efficacy with convenient pre-filled syringe (PFS) and autoinjector/pen (AI)[1],[2] Patient-reported outcomes from FEATURE and JUNCTURE show high patient satisfaction with secukinumab PFS and AI self-admin

Pharmacology - Health - 21.03.2014
Novartis announces US FDA approval of Xolair for chronic idiopathic urticaria (CIU)
Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Health - Pharmacology - 21.03.2014
Novartis announces start of new secukinumab (AIN457) versus Stelara (ustekinumab) phase IIIb head-to-head psoriasis study at AAD 2014
Novartis announces start of new secukinumab (AIN457) versus Stelara (ustekinumab) phase IIIb head-to-head psoriasis study at AAD 2014 Global phase IIIb head-to-head study of secukinumab versus Stelar

Pharmacology - Health - 20.03.2014
Novartis introduces Lucentis in state of the art pre-filled syringe
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Health - Pharmacology - 19.03.2014
Novartis reports data at EBCC-9 for secondary survival endpoint of Afinitor trial in HR+/HER2- advanced breast cancer
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Health - Pharmacology - 13.03.2014
Novartis Bexsero meningitis B vaccine receives clinical recommendation for use in infants and adolescents in Australia
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 07.03.2014
Novartis announces positive Phase III study for Jakavi in patients with rare blood cancer polycythemia vera
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 06.03.2014
Novartis announces Xolair approved in EU as first and only licensed therapy for chronic spontaneous urticaria (CSU) patients unresponsive to antihistamines
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 28.02.2014
Novartis marks Rare Disease Day with call for more research to understand and find treatments for rare diseases
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a] novartis (p) com

Pharmacology - Health - 26.02.2014
Novartis extends leadership in clinical trial data transparency, reinforcing its support of clinical research and innovation
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a] novartis (p) com

Business / Economics - Pharmacology - 25.02.2014
Novartis shareholders approve all resolutions proposed by Novartis Board of Directors
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 21.02.2014
Novartis shows continued commitment in Japan with Lucentis approval in fourth Japanese indication, diabetic macular edema
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a] novartis (p) com

Health - Pharmacology - 19.02.2014
Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 17.02.2014
Novartis expands cancer immunotherapy research program with acquisition of CoStim
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Business / Economics - Pharmacology - 29.01.2014
Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Business / Economics - 27.01.2014
Novartis recognized among world’s most sustainable companies in Corporate Knights Global 100
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 24.01.2014
Novartis reports positive opinion from CHMP for Xolair in severe form of skin disease CSU, a debilitating form of hives and chronic itch
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 24.01.2014
Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 12.01.2014
Hervé Hoppenot, President of Novartis Oncology, leaves Novartis to pursue career opportunity outside of organization
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 19.12.2013
Sandoz begins Phase III clinical trial for biosimilar adalimumab
Sandoz advances leading biosimilars pipeline by strengthening Immunology portfolio Global program marks Sandoz' sixth biosimilar molecule to enter Phase III testing Trial will support registration in

Health - Pharmacology - 18.12.2013
Sandoz receives first approval for AirFluSal Forspiro
Novel inhaler approved for patients with asthma and COPD Approval follows completion of EU decentralized procedure (DCP) AirFluSal Forspiro strengthens Sandoz respiratory portfolio and reinforces com

Pharmacology - Health - 09.12.2013
Novartis drug Jakavi improved overall survival of patients with myelofibrosis in four separate analyses of long-term Phase III studies
In two Phase III studies, Jakavi reduced the risk of death and maintained spleen reductions at three years compared to conventional therapy and placebo Similar survival benefit seen in patients with and without high-risk mutations Separate analysis shows Jakavi may increase the probability of 10-year survival of myelofibrosis patients by more than 50% compared to conventional therapy Jakavi is the only JAK inhibitor approved in more than 50 coun

Pharmacology - Health - 09.12.2013
New five-year data support superiority of Novartis drug Tasigna over Glivec in newly diagnosed Ph+ CML patients
ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Glivec Data demonstrated higher rates of early and deeper molecul

Health - Pharmacology - 07.12.2013
Novartis highlights research on investigational, personalized’T cell therapy CTL019 in patients with forms of acute and chronic leukemia
Data at ASH show increased scientific understanding of CTL019 and its potential role in the treatment of certain types of lymphocytic leukemia , , , Presentations include findings that 19 of 22 pediatric patients with acute lymphoblastic leukemia ( ALL) (86%) experienced complete remissions Novartis and Penn exclusive global collaboration to develop chimeric antigen receptor (CAR) technology is moving forward with the goal of expanding clinical

Pharmacology - Health - 06.12.2013
Novartis investigational compound LBH589 significantly extended time without disease progression in Phase III multiple myeloma study
Study of LBH589 plus bortezomib and dexamethasone met primary endpoint of extending PFS compared to bortezomib plus dexamethasone and placebo LBH589 has potential to be the first in its class of anticancer agents available to patients with multiple myeloma Data will be presented at an upcoming medical congress and discussed with regulatory authorities worldwide Basel, December 6, 2013 - Novartis today announced that results of a Phase III trial

This site uses cookies and analysis tools to improve the usability of the site. More information. |